A new investigation found that activating the transcription factor MEF2C triggers intrinsic apoptosis and reverses cisplatin resistance in ovarian cancer cells. The authors demonstrated MEF2C-mediated transcriptional programs that restore apoptotic signaling and sensitize tumors to platinum chemotherapy. The results point to transcriptional modulation as a strategy to overcome chemoresistance and warrant preclinical combination studies to evaluate safety and efficacy.